Ha Choi Ji, Wah Yee Sook, Kim Mee J, Nguyen Loan, Ho Lee Jeong, Kang Ji-One, Hesselson Stephanie, Castro Richard A, Stryke Doug, Johns Susan J, Kwok Pui-Yan, Ferrin Thomas E, Goo Lee Min, Black Brain L, Ahituv Nadav, Giacomini Kathleen M
Department of Pharmacology, Ewha Womans University, Seoul, Korea.
Pharmacogenet Genomics. 2009 Oct;19(10):770-80. doi: 10.1097/FPC.0b013e328330eeca.
Human multidrug and toxin extrusion member 1, MATE1 (SLC47A1), plays an important role in the renal and biliary excretion of endogenous and exogenous organic cations including many therapeutic drugs. In this study, we characterized the transcriptional effects of five polymorphic variants and six common haplotypes in the basal promoter region of MATE1 that were identified in 272 DNA samples from ethnically diverse US populations.
We measured luciferase activities of the six common promoter haplotypes of MATE1 using in-vitro and in-vivo reporter assays.
Haplotypes that contain the most common variant (mean allele frequency in four ethnic groups: 0.322), g.-66T>C, showed a significant decrease in reporter activities compared to the reference. Two transcription factors, activating protein-1 (AP-1) and activating protein-2 repressor (AP-2rep), were predicted to bind to the promoter in the region of g.-66T>C. Results from electrophoretic mobility shift assays showed that the g.-66T allele, exhibited greater binding to AP-1 than the g.-66C allele. AP-2rep inhibited the binding of AP-1 to the MATE1 basal promoter region, and the effect was considerably greater for the g.-66T>C. These data suggest that the reduced transcriptional activity of g.-66T>C results from a reduction in the binding potency of the transcriptional activator, AP-1, and an enhanced binding potency of the repressor, AP-2rep to the MATE1 basal promoter region. Consistent with the reporter assays, MATE1 mRNA expression levels were significantly lower in kidney samples from individuals who were homozygous or heterozygous for g.-66T>C in comparison with samples from individuals who were homozygous for the g.-66T allele.
Our study suggests that the rate of transcription of MATE1 is regulated by AP-1 and AP-2rep and that a common promoter variant, g.-66T>C may affect the expression level of MATE1 in human kidney, and ultimately result in variation in drug disposition and response.
人类多药及毒素外排成员1(MATE1,SLC47A1)在肾脏和胆汁对内源性及外源性有机阳离子(包括许多治疗药物)的排泄中发挥重要作用。在本研究中,我们对MATE1基因基础启动子区域的五个多态性变体和六个常见单倍型的转录效应进行了表征,这些变体和单倍型是在来自美国不同种族人群的272份DNA样本中鉴定出来的。
我们使用体外和体内报告基因检测法测量了MATE1基因六个常见启动子单倍型的荧光素酶活性。
包含最常见变体(四个种族群体中的平均等位基因频率:0.322)g.-66T>C的单倍型与参照相比,报告基因活性显著降低。预测有两个转录因子,即激活蛋白-1(AP-1)和激活蛋白-2阻遏物(AP-2rep)可结合到g.-66T>C区域的启动子上。电泳迁移率变动分析结果表明,g.-66T等位基因与AP-1的结合比g.-66C等位基因更强。AP-2rep抑制AP-1与MATE1基因基础启动子区域的结合,对于g.-66T>C而言,这种抑制作用更为显著。这些数据表明,g.-66T>C转录活性降低是由于转录激活因子AP-1的结合能力下降以及阻遏物AP-2rep与MATE1基因基础启动子区域的结合能力增强所致。与报告基因检测结果一致,在g.-66T>C位点为纯合子或杂合子的个体的肾脏样本中,MATE1 mRNA表达水平显著低于g.-66T等位基因纯合子个体的样本。
我们的研究表明,MATE1基因的转录速率受AP-1和AP-2rep调控,一个常见的启动子变体g.-66T>C可能会影响MATE1在人肾脏中的表达水平,并最终导致药物处置和反应的差异。